Primary effusion lymphoma (PEL) is an aggressive form of non-Hodgkin's B-cell lymphoma associated with infection by Kaposi's sarcoma-associated herpes virus (KSHV). ( þ )-JQ1 and I-BET151 are two recently described novel small-molecule inhibitors of BET bromodomain chromatin-associated proteins that have shown impressive preclinical activity in cancers in which MYC is overexpressed at the transcriptional level due to chromosomal translocations that bring the MYC gene under the control of a superenhancer. PEL cells, in contrast, lack structural alterations in the MYC gene, but have deregulated Myc protein due to the activity of KSHV-encoded latent proteins. We report that PEL cell lines are highly sensitive to bromodomain and extra-terminal (BET) bromodomain inhibitors-induced growth inhibition and undergo G 0 /G 1 cell-cycle arrest, apoptosis and cellular senescence, but without the induction of lytic reactivation, upon treatment with these drugs. Treatment of PEL cell lines with BET inhibitors suppressed the expression of MYC and resulted in a genome-wide perturbation of MYC-dependent genes. Silencing of BRD4 and MYC expression blocked cell proliferation and cell-cycle progression, while ectopic expression of MYC from a retroviral promoter rescued cells from ( þ )-JQ1-induced growth arrest. In a xenograft model of PEL, ( þ )-JQ1 significantly reduced tumor growth and improved survival. Taken collectively, our results demonstrate that the utility of BET inhibitors may not be limited to cancers in which genomic alterations result in extremely high expression of MYC and they may have equal or perhaps greater activity against cancers in which the MYC genomic locus is structurally intact and c-Myc protein is deregulated at the post-translational level and is only modestly overexpressed.
INTRODUCTION
Infection with Kaposi's sarcoma-associated herpes virus (KSHV) is the commonest cause of malignancy among patients with AIDS and one of the commonest causes of malignancies among young adults in many parts of the world. 1, 2 The prognosis of KSHVassociated primary effusion lymphoma (PEL) is extremely poor with a median survival of less than 3 months in most reported studies. [3] [4] [5] Thus, there is an urgent need for novel molecularly targeted therapies for PEL.
Bromodomains are small evolutionarily conserved domains present in many chromatin-associated proteins and almost all nuclear histone acetyltransferases. 6, 7 These domains recognize acetylated-lysine residues in histones and regulate proteinprotein interactions involved in chromatin-mediated cellular gene transcription, cell proliferation and viral transcriptional activation. 6, 7 The human genome contains 41 bromodomain proteins that have been implicated in a wide range of diseases including cancer, inflammation, obesity, diabetes, infectious diseases and cardiovascular disorders. 7 The bromodomain and extra-terminal (BET) subfamily is represented by BRD2, BRD3, BRD4 and BRDT, and its members share similar domain structure consisting of two highly conserved amino-terminal bromodomains. Several recent studies have shown that BRD4 plays a key role in hematological malignancies. [8] [9] [10] [11] These studies have been facilitated by the recent development of small-molecule compounds, ( þ )-JQ1 and I-BET151, which displace BET bromodomain proteins from chromatin by competitively binding to the acetyl-lysine recognition pocket in histones. 12, 13 Thus, pharmacological inhibition of BRD4 by ( þ )-JQ1 and I-BET151 in a mouse model of MLL-fusion-induced acute myeloid leukemia was shown to block disease progression in vitro and in vivo. 9, 10 Treatment with BET inhibitors was also shown to have activity in preclinical models of multiple myeloma and Burktitt's lymphoma. 8, 14 The antiproliferative effects of BET inhibitors in the above disease models were associated with a block in the transcription of key oncogenes, most notably MYC, followed by genome-wide suppression of c-Myc-dependent target genes. 8, 9, 14 However, since BRD4 is ubiquitously expressed, it was unclear why its inhibition would result in specific downregulation of c-Myc. A recent study addressed this question using the multiple myeloma cell line MM1.S and reported that BRD4, along with Mediator coactivator complex, is present at extremely high levels in a small set of exceptionally large enhancers, called super-enhancers. 15 The MM1.S cell line carries an IgH-MYC rearrangement that places the MYC gene under the control of the IgH super-enhancer. 15 Treatment of MM1.S cells with ( þ )-JQ1 was found to lead to preferential loss of BRD4 and its associated co-factors at super-enhancers and caused preferential loss of transcription at genes associated with superenhancers, including the MYC oncogene. 15 Based on these results, BET inhibitors would be expected to have activity primarily against cancers in which the MYC gene comes under the control of a superenhancer and is highly overexpressed at the transcriptional level.
c-Myc has also been shown to be required for proliferation of PEL cells and for maintenance of KSHV latency. 16 However, while MYC is frequently deregulated at the genomic/transcriptional level in human cancers, including cancers against which BET inhibitors have shown activity, the MYC genomic locus is structurally intact in PEL. 3 Instead, c-Myc is deregulated in PEL at the posttranslational level due to the activity of two KSHV latent proteins, LANA and vIRF3/LANA2, which enhance the stability of c-Myc and stimulate its transcriptional activity. [17] [18] [19] To examine whether BET inhibitors may also have activity against cancers in which MYC is not upregulated at the transcriptional level, we examined their activity against PEL cells. We demonstrate that the utility of BET inhibitors is not limited to cancers in which genomic alternations bring the MYC genes under the control of a superenhancer and these compounds may have equal or greater activity against cancers in which the MYC genomic locus is structurally intact and c-Myc protein is deregulated at the post-translational level.
RESULTS
Antiproliferative effects of ( þ )-JQ1 on PEL cell lines To explore the effect of BRD4 inhibitors on the survival and proliferation of PEL cells, we treated four PEL-derived cell lines,
, with increasing doses of ( þ )-JQ1. As shown in Figure 1a , treatment with increasing doses of ( þ )-JQ1 for a period of 5 days strongly reduced the survival of BC1, BC3
and BCBL1 in a dose-dependent manner as measured by an MTS assay (IC 50 ¼ 250, 380, and 380 nM for BC1, BC3 and BCBL1, respectively). ( þ )-JQ1 also blocked the proliferation of JSC1 cells, albeit at slightly higher doses (IC 50 ¼ 790 nM). In contrast, Burkitt's lymphoma-derived Namalwa (KSHV À /EBV þ ) cells were relatively resistant to ( þ )-JQ1 (IC 50 ¼ 1130 nM). Treatment with ( À )-JQ1, an inactive enantiomer of ( þ )-JQ1, 12 had no significant growthinhibitory effect on any of the tested cell lines (Figure 1a ). To further demonstrate the sensitivity of PEL cells to ( þ )-JQ1, we next examined its effect on a panel of leukemia and lymphoma cell lines of diverse lineages. The IC 50 of ( þ )-JQ1 for the non-PEL cell lines in this panel ranged from 820 nM to 45 mM, which were considerably higher than its IC 50 for the PEL cell lines (Table 1) . Collectively, the above results demonstrate that the PELderived cell lines are remarkably sensitive to ( þ )-JQ1-induced growth inhibition.
Antiproliferative effect of I-BET151 on PEL cell lines To next demonstrate that the observed growth-inhibitory effect of ( þ )-JQ1 on PEL cell lines is a class effect, we took advantage of I-BET151, a structural analog of JQ1. 10 Treatment with I-BET151 resulted in a dose-dependent reduction in the proliferation of all tested cell lines. However, similar to the results with ( þ )-JQ1, the IC 50 values of I-BET151 for PEL cell lines (220, 460 and 330 nM for BC1, BC3 and BCBL1 cells) were significantly lower than their IC 50 for non-PEL cells (970, 970, 1220, 760 and 950 nM for BJAB, Namalwa, Jurkat, MM1S and U266 cell lines, respectively) ( Figure 1b and Table 1 ). Taken collectively, the above results Antiproliferative effects of ( þ )-JQ1and I-BET151 on UM-PEL-1 and UM-PEL-3 cells Owing to its rarity, many studies on PEL are limited to PEL-derived cell lines that may deviate from the original tumors seen in the patient due to culture-induced adaptations. To circumvent this problem, we tested the effect of BET inhibitors on UM-PEL-1 and UM-PEL-3 cell models. 20, 21 These models were established by transferring freshly isolated human PEL cells into the peritoneal cavities of NOD/SCID mice and have been subsequently maintained by serial propagation in vivo without in vitro cell growth to avoid the changes in KSHV gene expression evident in cultured cells. Table 3 ). In contrast, ( þ )-JQ1 had no major effect on cell-cycle progression in Namalwa cells (Figure 2a) . Thus, BET Figure S1a) . We also evaluated the effect of increasing doses of ( þ )-JQ1 on the alterations in the expression of pro-and antiapoptotic proteins. We did not observe a significant increase in the cleavage of PARP or downregulation of Mcl-1 upon treatment with ( þ )-JQ1 in BC1, BCBL1 and Namalwa cells (Supplementary Figure S1b) . A modest reduction in Bcl-xL expression was seen upon treatment of BC1 cells with increasing doses of ( þ )-JQ1, but was not seen in BCBL1 and Namalwa cells (Supplementary Figure S1b) . We also evaluated the effect of JQ1 on cellular senescence. PEL cells were treated with ( þ )-JQ1 and subsequently stained with b-galactosidase, a marker for cellular senescence. Consistent with their relative sensitivity to ( þ )-JQ1-mediated growth inhibition, BC1, BC3 and BCBL1 cells showed strong b-galactosidase staining following ( þ )-JQ1 treatment, while JSC1 and Namalwa cells showed weak to no increase in staining, respectively (Figure 3b ). The increase in b-galactosidase staining in BC1, BC3 and BCBL1 cells was accompanied by upregulation of p27 (Figure 3c ), a known marker of cellular senescence. 22 As a control, we also evaluated the effect of ( À )-JQ1 on induction of apoptosis and cellular senescence in PEL cells and observed no significant effect (Supplementary Figure S2) . Taken together, treatment of PEL cells with BET inhibitors results in a phenotype of reduced proliferation, G 0 /G 1 cell-cycle arrest, mild increase in apoptosis and induction of cellular senescence.
Analysis of differential gene expression in PEL following JQ1 treatment To test the effect of BET inhibition on gene transcription, BC1, BCBL1 and JSC1 cells were treated with ( þ )-JQ1 (500 nM) for 8 h followed by genome-wide transcriptome analysis using Illumina's RNA-Seq platform. Unsupervised hierarchical clustering separated samples according to their treatment group, indicating a common transcriptional response to treatment with ( þ )-JQ1 (Figure 4a ). Rather than inducing non-specific changes in gene expression, ( þ )-JQ1 induced significant changes in a limited number of genes. Thus, there were more than 350 genes (229 down-and 129 upregulated genes) whose expression was changed X2 fold in all three cell lines. We used a GSEA program to identify functional gene sets whose expression changed significantly with ( þ )-JQ1 treatment in PEL cells. 23 For this purpose, we focused on gene sets containing genes co-regulated in response to genetic and chemical perturbations. Among the top gene signatures identified by this analysis were two gene sets (BENPORATH_MYC_MAX_TARGETS (Figure 5a ). In contrast, ( þ )-JQ1 had no significant inhibitory effect on MYC expression in the Namalwa cells (Figure 5a ). We also observed a dose-dependent decline in c-Myc protein expression in BC1, BC3 and BCBL1 cells (Figure 5b ), which was associated with depletion of chromatin-bound c-Myc, as measured by an ELISA-based DNAbinding assay (Figure 5c ). The baseline level of c-Myc protein was higher in JSC1 cells as compared to the other PEL cell lines, and its significant residual expression was observed in the ( þ )-JQ1-treated cells (Figure 5b ), which probably contributed to their reduced sensitivity to the drug in the MTS assay (Table 1) . Additional support for the hypothesis that the level of c-Myc is a key determinant of response to ( þ )-JQ1 was provided by studies on Namalwa cells, which are relatively resistant to ( þ )-JQ1 (IC 50 ¼ 1130 nM) ( Table 1 ). The basal level of c-Myc was significantly higher in Namalwa cells as compared to the PEL cell lines and remained higher following treatment with ( þ )-JQ1 (Figure 5b) . A close correlation between the response to BET inhibitors and c-Myc level was also observed in experiments involving treatment with I-BET151. As shown in Figure 5d , I-BET151 resulted in a dose-dependent decline in c-Myc protein levels in the BC1 and BC3 cell lines. However, similar to Namalwa cells, the basal level of c-Myc in the I-BET151-resistant Jurkat cells was relatively high as compared to the PEL cell lines and was not significantly affected by treatment with the drug (Figure 5d) . Collectively, the above results support the hypothesis that the level of c-Myc is a key determinant of response to BET inhibitors.
Finally, we used qRT-PCR analysis to examine the effect of ( þ )-JQ1 on the expression of two known downstream MYC target genes, MYB and TERT. We also included TYRO3, a gene known to be downregulated by ( þ )-JQ1, in the analysis. Figure S3) . In contrast, ( þ )-JQ1 treatment had no significant impact on the expression of MYB, TERT and TYRO3 in the Namalwa cells (Figure 5e ). Thus, sensitivity to ( þ )-JQ1 correlates closely with the degree of downregulation of MYC-target genes.
Suppression of BRD4 and c-Myc expression reduces PEL cell viability In the case of ( þ )-JQ1 exerting its effect on PEL cells by inhibiting BRD4 and downregulating c-Myc, silencing of BRD4 and MYC by short hairpin RNAs (shRNAs) would be expected to resemble the effect of ( þ )-JQ1 treatment. To test this hypothesis, we generated stable clones of BC1 cells expressing tetracycline-inducible H1 promoter (H1/TO)-driven shRNAs targeting BRD4 and MYC, respectively. Treatment of BC1-H1/TO-BRD4-shRNA and BC1-H1/ TO-MYC-shRNA cells with doxycycline resulted in downregulation of BRD4 and c-Myc, respectively, as determined by western blotting (Figure 6a ). More importantly, doxycycline treatment of BC1-H1/TO-BRD4-shRNA and BC1-H1/TO-MYC-shRNA cells was accompanied by approximately 40% and 60% reduction in cellular proliferation (Figure 6b and Supplementary Table 4) , respectively, and G 0 /G 1 cell-cycle arrest (Figure 6c) , thus resembling the phenotype of ( þ )-JQ1-treated cells. In contrast, doxycycline treatment had no significant effect on cell proliferation or cellcycle progression in BC1 cells expressing a scrambled shRNA as a control (Figures 6b and c) .
Reconstitution of MYC rescues ( þ )-JQ1-treated cells from growth suppression To confirm the functional involvement of c-Myc downregulation in the antiproliferative effect of ( þ )-JQ1, we studied whether ectopic expression of c-Myc from a retroviral-derived promoter would rescue them from JQ1-induced growth inhibition. For this purpose, we generated BC1 cells stably expressing either wildtype c-Myc or its FLAG-tagged T58A mutant, which is resistant to phosphorylation-induced degradation. Consistent with the increased stability of the T58A mutant, c-Myc protein expression was modestly increased in the wild-type c-Myc-transduced cells but strongly increased in the c-Myc-T58A mutant-transduced Table 5 ). Taken collectively, these results demonstrate that downregulation of Myc has a major role in the growth-inhibitory effect of BET inhibitors in PEL cells.
Lack of induction of KSHV lytic replication by ( þ )-JQ1 in PEL
Myc is required for maintenance of KSHV latency and its shRNAmediated silencing results in the induction of KSHV Replication and Transcription Activator (RTA), the master regulator of KSHV lytic replication. 16 Therefore, we next examined whether treatment with ( þ )-JQ1 results in lytic reactivation of the virus, as measured by expression of RTA using immunoblotting. As a positive control, we used BCBL1-TREx-RTA cells, which express RTA from a tetracycline-inducible promoter and undergo a complete cycle of viral replication upon treatment with doxycycline. 26 While treatment of BCBL1-TREx-RTA cells with doxycycline resulted in robust induction of RTA, treatment of PEL cell lines with ( þ )-JQ1 failed to do so (Figure 8a ). We have previously generated a reporter cell line, designated 293-PAN-Luc, which expresses the firefly luciferase gene under the control of KSHV PAN promoter and responds to infection with KSHV by increasing luciferase activity in a sensitive and quantitative manner. 27 To confirm the lack of lytic replication induction by ( þ )-JQ1, cell-free supernatants from ( þ )-JQ1-treated PEL cells were applied to 293PAN-Luc cells and assessed for increase in luciferase activity. As shown in Figure 8b , exposure of 293PAN-Luc cells to supernatant from doxycycline-treated BCBL1-TREx-RTA cells led to a significant increase in luciferase activity, whereas supernatant from ( þ )-JQ1-treated PEL cells failed to do so. Thus, ( þ )-JQ1-induced growth inhibition and apoptosis is not accompanied by production of infectious virions.
( þ )-JQ1 exhibits in vivo growth-inhibitory activity against PEL in mouse xenografts To check the in vivo efficacy of ( þ )-JQ1 against PEL, we injected the BC1 cells expressing an RSV-promoter-driven firefly luciferase cDNA (BC1-Luc) intraperitoneally into NOD/SCID mice. Animals with established tumors, as detected by bioluminescence imaging on day 3, were randomly assigned to vehicle control (n ¼ 12) and ( þ )-JQ1 (50 mg/kg twice daily for 11 days; n ¼ 12). Animals treated with ( þ )-JQ1 showed reduced tumor growth as determined by bioluminescence imaging and measurement of body weight, a surrogate for tumor-induced ascites (Figure 9a-c) . In addition, the median survival of ( þ )-JQ1-treated animals was significantly improved as compared to the control vehicle-treated animals (27 vs 20 days; P ¼ 0.0088) (Figure 9d ).
DISCUSSION
As a master regulator of cell proliferation, c-Myc contributes to the disease progression in a number of human cancers, making it a prime therapeutic target. 28 However, conventional approaches to directly block c-Myc function using small-molecule compounds have proven to be largely ineffective. Using a first-in-class inhibitor of BET bromodomains, which block Myc transcription and function indirectly through displacement of chromatin-bound coactivator proteins, we provide evidence that PEL cell lines are sensitive to BET inhibitors in vitro and in vivo. Indeed, the involvement of c-Myc in the inhibitory effects of BET inhibitors in PEL cell lines is supported by the following lines of evidence. First, we observed significant downregulation of c-Myc transcript and protein levels in PEL cell lines following treatment with BET inhibitors, which was accompanied by depletion of nuclear c-Myc. Second, we observed a marked enrichment of downstream target genes of c-Myc among the genes perturbed in PEL cell lines following treatment with BET inhibitors. Third, there was a good correlation between the sensitivity to BET inhibitors and degree of downregulation of MYC and its downstream target genes. Fourth, shRNA-mediated silencing of MYC and BRD4 in BC1 cells resulted in cell-cycle arrest, thus resembling the cell-cycle effects observed in cells treated with the BET inhibitors. Consistent with our results in BC1 cells, knockdown of MYC has been also reported to induce cell-cycle arrest in the PEL-derived BC3 cell line. 16 Finally, overexpression of c-Myc via an ectopic retroviral promoter rescued PEL cells from ( þ )-JQ1-induced growth inhibition.
BET inhibitors have been previously shown to downregulate MYC and possess selective activity against Burkitt's lymphoma (BL) and multiple myeloma, 8, 14 which carry chromosomal translocations involving the MYC locus. 29, 30 The selective downregulation of MYC by ( þ )-JQ1 has been attributed to the preferential loss of BRD4 at the super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. 15 In contrast, we demonstrate the activity of BET inhibitors against PEL, in which the MYC locus is structurally intact. More importantly, we observed that PEL cells are highly sensitive to BET bromodomain inhibitors. Indeed, the IC 50 of both ( þ )-JQ1 and I-BET151 for PEL cell lines was generally lower than their IC 50 for a panel of hematologic cell lines of diverse origins, including cell lines derived from multiple myeloma and BL. Although the precise reason for the remarkable sensitivity of PEL cell lines to BET inhibitors is not known at the present, our results suggest that the relative level of the c-Myc protein may play a role in this process. The basal and the posttreatment levels of the c-Myc protein were significantly higher in the Namalwa and Jurkat cells lines that are relatively resistant to BET inhibitors as compared to the drug-sensitive PEL cell lines. Even among the PEL cell lines, the basal and post-treatment levels of c-Myc protein correlated well with their resistance to BET inhibitors. Thus, a possible explanation for the greater sensitivity of PEL cells to BET inhibitors may lie in their relatively modest expression of the c-Myc protein that is easily suppressed by the drug treatment. The modest elevation of c-Myc in PEL cells may in turn reflect the fact that the PEL cells lack structural alterations in the MYC gene 3 and the elevation of c-Myc activity in these cells is primarily due to post-translational mechanisms involving enhanced stabilization or activity of the protein. [17] [18] [19] Thus, while the current paradigm suggests that the ideal candidates for BET inhibitors are those cancers in which MYC is highly overexpressed due to the activity of super-enhancers, 15 our results suggest that such cancers may not be the most sensitive to treatment with these compounds because they will require much higher doses of the inhibitors to completely downregulate c-Myc expression from the extremely high basal levels. Instead, our study suggests that cancers such as PEL, which lack structural alterations at the MYC locus and express only modestly high levels of the c-Myc protein, are probably equally good or perhaps better candidates for treatment with the BET inhibitors.
Although our results suggest a key role of c-Myc downregulation in the cellular response to BET inhibitors, perturbation in other cellular and viral genes and signaling pathways is also likely to contribute to this process. Additionally, while ectopic expression of c-Myc successfully protected PEL cells from low doses of ( þ )-JQ1, it failed to confer protection when exposed to higher doses of the drug. Thus, the effect of BET inhibitors on Mycindependent pathways may also contribute to their growthinhibitory effects against PEL cells. Indeed, I-BET has been shown to block the expression of a number of inflammatory genes that have been implicated in the pathogenesis of KSHV-associated malignancies. 13 Additionally, KSHV-encoded LANA tethers viral genomes to host mitotic chromosomes that ensure maintenance of viral episomes in dividing cells. 31, 32 The interaction between the carboxy-terminal domain of LANA and host chromatin is mediated via BRD4. 33, 34 BRD4 was also shown to associate with mitotic chromosomes throughout mitosis and co-localize with LANA and the KSHV episomes on host mitotic chromosomes. 33, 34 Thus, it is conceivable that the effect of BET inhibitors on LANA-BRD4 interactions and KSHV episome maintenance may also contribute to its growth-inhibitory effects in PEL cells.
Finally, induction of lytic replication is increasingly believed to have an important role in KSHV tumorigenesis. 35 Silencing of Myc was recently shown to induce expression of RTA and lytic protein K8. 16 In contrast, we observed that ( þ )-JQ1 did not induce expression of lytic genes or production of infectious virions, thereby allaying these safety concerns. While the exact mechanism for the lack of lytic reactivation by ( þ )-JQ1 is not clear at the present, its effects on Myc-independent genes may be responsible for this process. In summary, we have used first-in-class BET inhibitors to provide strong in vitro and in vivo preclinical rationale for targeting BRD4 and MYC for the treatment of PEL. Epigenetic modulators affect thousands of genes and many targets of BET inhibitors have already been described in the literature. 9, 11, 12, 15, 36 Although our study does not identify any new target of the BET inhibitors, it addresses a more pressing and clinically relevant issue regarding the therapeutic development of these compounds: namely, the range of cancers against which these compounds are likely to show activity. We demonstrate that the utility of BET inhibitors may not be limited to malignancies in which c-Myc is highly overexpressed due to genomic alterations that bring the MYC gene under the control of a super-enhancer and that they may have equal or even greater activity against cancers in which the MYC genomic locus is structurally intact and c-Myc is only modestly overexpressed. Thus, our results considerably extend the range of cancers that are candidates for clinical testing of BET inhibitors.
MATERIALS AND METHODS

Cell lines and reagents
293FT, BC1, BC3, BCBL1, JSC1, Namalwa, Jurkat, BJAB, H9 and K562 cells were obtained from ATCC (Manassas, VA, USA); human multiple myeloma cell lines, MM1S and U266 were from Dr Ellen Vitetta (UT Southwestern Medical Center, Dallas, TX, USA) and Karpass-299 and HPB-ALL were from Dr Alan Epstein (USC). UM-PEL-1 and UM-PEL-3 were provided by Drs Izidore Lossos and Juan Ramos, respectively (both from University of Miami, FL, USA). 293-PAN-Luc and BCBL1-TREx-RTA cells have been described previously.
27 BC1-Luc cells were generated by infection with a retroviral vector encoding a Rous Sarcoma Virus promoter-driven firefly luciferase construct. ( þ )-JQ1 and its inactive enantiomer ( À )-JQ1 were generously provided by Dr James Bradner (Dana-Farber Cancer Institute, Boston, MA, USA). I-BET151 was from ChemieTek (Indianapolis, IN, USA) and Doxycycline was purchased from Sigma (St Louis, MO, USA).
Retroviral and lentiviral constructs
Retroviral constructs containing c-Myc-T58A and Flag epitope-tagged wildtype c-Myc were obtained from Addgene (Cambridge, MA, USA). Recombinant retroviruses were generated and used to infect PEL cell lines as described previously. 37 For generation of shRNA encoding lentiviral vectors, shRNA oligonucleotides (Supplementary Table 2 ) directed against human c-Myc and BRD4 mRNAs were annealed and cloned into a modified pENT entry vector containing a tetracycline-inducible H1 promoter (H1/ TO). The cassette containing the H1/TO promoter along with the shRNA hairpin was concatenated as described earlier 37 so as to result in eight copies of the H1/TO-shRNA cassettes in each vector. Recombination-based subcloning was used to transfer the concatenated H1/TO-shRNA cassettes into a pSLIK destination vector. 38 293FT cells were used to induce virus production as described previously. 37 The packaged virus was then used to infect PEL cells and positive clones were selected with G418. Doxycycline (500 ng/ml) was used to induce the expression of shRNAs.
Animal studies
Five-week-old female NOD/SCID mice (NCI) were injected intraperitoneally (IP) with 2 Â 10 7 BC1-Luc cells. To assess establishment of tumors, mice were imaged 3 days post inoculation using an IVIS Spectrum Imaging system (Perkin Elmer's, Waltham, MA, USA). Mice were randomly segregated into two treatment groups (vehicle control and ( þ )-JQ1, n ¼ 12 per group) and were treated intraperitoneally twice daily with ( þ )-JQ1 (50 mg/kg) or vehicle control (10% b-cyclodextrin, Sigma). Bioluminescence imaging and body weight (a surrogate for tumor-induced ascites) were used to assess tumor burden. All animal procedures were performed under IACUC-approved protocols.
Statistical analyses
Two-tailed paired Student's t-test was used to test for differences between two groups. Differences with a Pp0.05 were considered as statistically significant. All experiments were repeated a minimum of two times with duplicate/triplicate samples.
